Heilongjiang ZBD Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Heilongjiang ZBD Pharmaceutical has a total shareholder equity of CN¥8.2B and total debt of CN¥3.3B, which brings its debt-to-equity ratio to 40.5%. Its total assets and total liabilities are CN¥12.7B and CN¥4.5B respectively. Heilongjiang ZBD Pharmaceutical's EBIT is CN¥685.3M making its interest coverage ratio -3. It has cash and short-term investments of CN¥966.2M.
Key information
40.5%
Debt to equity ratio
CN¥3.34b
Debt
| Interest coverage ratio | -3x |
| Cash | CN¥966.16m |
| Equity | CN¥8.25b |
| Total liabilities | CN¥4.45b |
| Total assets | CN¥12.70b |
Recent financial health updates
Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly
Sep 26
Does Heilongjiang ZBD Pharmaceutical (SHSE:603567) Have A Healthy Balance Sheet?
May 28Recent updates
We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings
Nov 05Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely
Oct 18Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly
Sep 26Does Heilongjiang ZBD Pharmaceutical (SHSE:603567) Have A Healthy Balance Sheet?
May 28Why Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings Are Better Than They Seem
May 06Insufficient Growth At Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Hampers Share Price
Apr 17Financial Position Analysis
Short Term Liabilities: 603567's short term assets (CN¥7.5B) exceed its short term liabilities (CN¥2.8B).
Long Term Liabilities: 603567's short term assets (CN¥7.5B) exceed its long term liabilities (CN¥1.7B).
Debt to Equity History and Analysis
Debt Level: 603567's net debt to equity ratio (28.8%) is considered satisfactory.
Reducing Debt: 603567's debt to equity ratio has reduced from 46% to 40.5% over the past 5 years.
Debt Coverage: 603567's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 603567 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 12:30 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Heilongjiang ZBD Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |